drugset / Trial / NCT02968914

Pharmacokinetic Comparability of Benralizumab Using Accessorized Pre-Filled Syringe or Autoinjector in Healthy Volunteers

NCT02968914

Phase 1 Completed 180 enrolled AstraZeneca Parexel · collab
RandomizedParallel-groupOpen-labelTreatment

Summary

An open-label, single dose Pharmacokinetic (PK) comparability study to demonstrate comparable drug exposure following Subcutaneous benralizumab administration by using accessorized pre-filled syringe (APFS) or autoinjector (AI) devices.

Timeline

Start
2017-01-04
Primary completion
2017-07-13
Completion
2017-07-13

Drugs

EvaluationDrugModalityDoseRoute
Subject Benralizumab Monoclonal antibody 30 mg Subcutaneous